221 related articles for article (PubMed ID: 22350498)
1. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
[TBL] [Abstract][Full Text] [Related]
2. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
Farnier M
Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Farnier M; Steinmetz A; Retterstøl K; Császár A
Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
[TBL] [Abstract][Full Text] [Related]
4. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Hernández Mijares A
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
6. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
Farnier M; Ducobu J; Bryniarski L
Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
[TBL] [Abstract][Full Text] [Related]
8. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
[TBL] [Abstract][Full Text] [Related]
9. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.
Guo J; Meng F; Ma N; Li C; Ding Z; Wang H; Hou R; Qin Y
Am J Cardiol; 2012 Nov; 110(9):1296-301. PubMed ID: 22840347
[TBL] [Abstract][Full Text] [Related]
13. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Lee SH; Cho KI; Kim JY; Ahn YK; Rha SW; Kim YJ; Choi YS; Choi SW; Jeon DW; Min PK; Choi DJ; Baek SH; Kim KS; Byun YS; Jang Y
Atherosclerosis; 2012 Mar; 221(1):169-75. PubMed ID: 22269152
[TBL] [Abstract][Full Text] [Related]
14. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Foucher C; Aubonnet P; Reichert P; Berli M; Schaeffer A; Calvo Vargas CG; Lochocka A; Belenky D; Koch HF;
Cardiovasc Ther; 2015 Dec; 33(6):329-37. PubMed ID: 26227087
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Farnier M; Retterstøl K; Steinmetz A; Császár A
Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
[TBL] [Abstract][Full Text] [Related]
16. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
Ramjattan BR; Callaghan DJ; Theiss U
Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
[TBL] [Abstract][Full Text] [Related]
19. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hyperlipidaemia with fenofibrate and related fibrates.
Filippatos T; Milionis HJ
Expert Opin Investig Drugs; 2008 Oct; 17(10):1599-614. PubMed ID: 18808320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
